Scholarlink

<p>Pharmacogenetics can enhance cardiovascular disease (CVD) treatment by tailoring drug therapy to genetic profiles and minimising trial-and-error approaches. Genetic variability influences responses to common CVD drugs, including antiplatelet drugs (clopidogrel and aspirin), anticoagulants (warfarin), statins, and antihypertensives (ACE inhibitors and β-blockers). Understanding genetic polymorphisms can improve efficacy and safety. Despite this progress, further research is needed to optimise pharmacogenomic applications and advance personalised medicine to improve CVD treatment outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月10日

查看全文
  • Ayat Shorbaji,
  • Peter Natesan Pushparaj,
  • Ayat B. Al-Ghafari,
  • Loubna Siraj Mira,
  • Mohammad Abdullah Basabrain,
  • Muhammad Imran Naseer,
  • Farid Ahmed,
  • Muhammad Abu-Elmagd,
  • Mahmood Rasool,
  • Sherin Bakhashab

摘要

Pharmacogenetics can enhance cardiovascular disease (CVD) treatment by tailoring drug therapy to genetic profiles and minimising trial-and-error approaches. Genetic variability influences responses to common CVD drugs, including antiplatelet drugs (clopidogrel and aspirin), anticoagulants (warfarin), statins, and antihypertensives (ACE inhibitors and β-blockers). Understanding genetic polymorphisms can improve efficacy and safety. Despite this progress, further research is needed to optimise pharmacogenomic applications and advance personalised medicine to improve CVD treatment outcomes.